Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas
NCT00074646 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2007-01-04
Summary
Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas
Conditions
- Glioblastoma
- Malignant Gliomas
Interventions
- DRUG
-
CC-8490
Sponsors & Collaborators
-
Celgene Corporation
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-12-31
- Completion
- 2005-06-30
Countries
- United States
Study Locations
More Related Trials
-
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
NCT01268566 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
NCT04166409 ·Status: RECRUITING ·Phase: PHASE3
-
A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression
NCT06828341 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
NCT07110246 ·Status: RECRUITING ·Phase: PHASE2
-
ANG1005 in Patients With Recurrent High-Grade Glioma
NCT01967810 ·Status: COMPLETED ·Phase: PHASE2
-
ZD6474 to Treat Advanced Brain Cancer in Patients
NCT00272350 ·Status: COMPLETED ·Phase: PHASE1
-
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
NCT00980343 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
NCT03649464 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors
NCT00088400 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
NCT00087451 ·Status: COMPLETED ·Phase: PHASE1
-
CC-5013 in Treating Patients With Recurrent Glioma
NCT00036894 ·Status: COMPLETED ·Phase: PHASE1
-
MK-2206 for Recurrent Malignant Glioma
NCT01249105 ·Status: WITHDRAWN ·Phase: PHASE2
-
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
NCT00002986 ·Status: COMPLETED ·Phase: PHASE1
-
Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma
NCT00005976 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
NCT03557359 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan in Treating Patients With Recurrent Glioma
NCT00003134 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
NCT07093814 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
NCT00093613 ·Status: COMPLETED ·Phase: PHASE1
-
First in Patient Study for PF-06840003 in Malignant Gliomas
NCT02764151 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas
NCT01229644 ·Status: TERMINATED ·Phase: PHASE2
-
Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma
NCT00002988 ·Status: COMPLETED ·Phase: PHASE1
-
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
NCT01095094 ·Status: TERMINATED ·Phase: PHASE2
-
Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
NCT00017264 ·Status: COMPLETED ·Phase: PHASE1
-
DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
NCT00805376 ·Status: COMPLETED ·Phase: PHASE1
-
Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
NCT00005859 ·Status: COMPLETED ·Phase: PHASE1/PHASE2